|API||Indication||Micronised / PSD||CEP||EU DMF||US DMF||JP DMF||KR DMF||CN DMF|
|Abediterol||Asthma and COPD|
|Arformoterol tartrate (A)||COPD||•||•|
|Arformoterol tartrate (D) p||COPD||•||•|
|Formoterol fumarate||Asthma and COPD||•||•||•||•||•||•|
|Glycopyrrolate bromide p||COPD||•||•||•||•|
|Indacaterol maleate p||Asthma and COPD||•||•||•|
|Montelukast sodium p||Asthma, allergic & seasonal rhinitis||•||•|
|Salmeterol xinafoate p||Asthma and COPD||•||•||•||•||•|
|Vilanterol||Asthma and COPD|
P = Patent applications/granted patents owned by Neuraxpharm
Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.
© Neuraxpharm / INKE. All rights reserved.